These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 1111876)
1. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy. Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876 [TBL] [Abstract][Full Text] [Related]
2. Long-term therapy of uremic osteodystrophy in adults with calcitriol. Moorthy AV; Harrington AR; Mazess RB; Simpson DP Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893 [TBL] [Abstract][Full Text] [Related]
3. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Massry SG; Goldstein DA; Malluche HH Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981 [No Abstract] [Full Text] [Related]
4. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol. Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103 [TBL] [Abstract][Full Text] [Related]
5. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy. Coburn JW; Brickman AS Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852 [No Abstract] [Full Text] [Related]
6. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy]. Reutter FW; Sieber R; Olah AJ; Dambacher MA Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567 [TBL] [Abstract][Full Text] [Related]
8. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy. Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529 [TBL] [Abstract][Full Text] [Related]
9. Proceedings: Bone demineralization in renal failure: a longitudinal study of the distal femur using photon absorptiometry. Overton TR; Silverberg DS AJR Am J Roentgenol; 1976 Jun; 126(6):1289-91. PubMed ID: 179410 [No Abstract] [Full Text] [Related]
10. 1,25-Dihydroxycholecalciferol in dialysed patients with clinically asymptomatic renal osteodystrophy. A controlled study. Fischer JA; Binswanger U Contrib Nephrol; 1980; 18():82-91. PubMed ID: 7353381 [TBL] [Abstract][Full Text] [Related]
12. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3. Naik RB; Robertson PW; Robinson BH; Dabek JT; James HM; Kanis JA Proc Eur Dial Transplant Assoc; 1977; 14():425-32. PubMed ID: 600960 [TBL] [Abstract][Full Text] [Related]
16. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033 [No Abstract] [Full Text] [Related]
17. Evidence that different vitamin D sterols have qualitatively different effects in man. Rasmussen H; Bordier P Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375 [No Abstract] [Full Text] [Related]
18. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy. Junor BJ; Catto GR Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411 [TBL] [Abstract][Full Text] [Related]